Use of sirt7 as novel cancer therapy target and method for treating cancer using the same
AssigneeCatholic University Industry Academic
InventorsSuk-Woo Nam, Jeong-Kyu Kim
Life of this patent
Estimating the term…
Loading patent…
AssigneeCatholic University Industry Academic
InventorsSuk-Woo Nam, Jeong-Kyu Kim
Estimating the term…
The present invention relates to the use of SIRT7 (sirtuin 7) as a marker for diagnosis of liver cancer. More specifically, the invention relates to a liver cancer diagnostic marker comprising SIRT7 gene, a liver cancer diagnostic composition, kit and microarray comprising the same, and a method of diagnosing liver cancer using the same. The invention also relates to a method for screening a substance capable of preventing or treating liver cancer by inhibiting the expression of SIRT7 gene or protein, and to a composition for preventing or treating liver cancer, which comprises the substance. The expression level of SIRT7 gene is higher in liver cancer tissue or cells than in non-liver cancer tissue or cells. Thus, when SIRT7 gene is used as a cancer diagnostic marker, cancer can be early diagnosed and predicted in a rapid and accurate manner, and it can be used as a target for development of an agent for preventing or treating cancer. Moreover, the invention is based on the finding that the expression of SIRT7 gene is indicative of the development and proliferation of cancer cells, and cell cycle transition, and thus the invention relates to the use of SIRT7 gene as a cancer diagnostic marker and to the anticancer use of inhibition of SIRT7 expression. In addition, the invention is based on the relationship between the SIRT7 expression and a specific miRNA, and thus relates to the use of the specific miRNA to regulate the cell cycle and inhibit tumor growth.
A cancer diagnostic marker comprising a substance for measuring the level of SIRT7 (sirtuin 7) gene or the level of SIRT7 protein.
A method of diagnosing or prognosing cancer, the method comprising the steps of:
A method for preventing or treating cancer by administration of a composition comprising, as an active ingredient, an antisense or siRNA (small interference RNA) oligonucleotide having a sequence complementary to a nucleotide sequence of the SIRT7 (sirtuin 7) gene.
A method of diagnosing or prognosing SIRT7-expressing cancer by examining the expression profiling of miR-125a-5p or miR-125b.
A method for treating SIRT7-expressing cancer by administering an anticancer composition against the cancer, wherein the anticancer composition comprises, as an active ingredient, an agent for promoting the expression or activity of miR-125a-5p or miR-125b.
A method of treating cancer by regulating the expression of SIRT7 gene using a miRNA selected from miR-125a-5p and miR-125b, the method comprising:
A method for screening a substance for treating liver cancer, the method comprising the steps of:
Dependencies are inferred from the claim text.